MarketInOut Stock Screener Log In | Sign Up
 

Bicara Therapeutics Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 10/23/2026
Bicara Therapeutics Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization1,143.47 mln
Float43.52 mln
Earnings Date11/17/2026

Piotroski F-Score

3 / 9
Below average

1-Year Forecast

35.67
Transformational upside

Relative Strength

45 / 100
Slightly lagging

Debt / Equity

0.00
Debt-free

ROE

-41.71
Deeply negative

ROA

-37.47
Deeply negative

Business Description

Bicara Therapeutics Inc. is a Boston-based medical research company focused on developing new treatments for solid tumor cancers. Founded in 2018, the company is advancing ficerafusp alfa, its primary drug candidate, which works by targeting two key biological pathways involved in tumor growth at the same time. This dual-action approach is designed to improve on existing cancer therapies and offer better outcomes for patients.

Key Fundamentals

EPS-3.08
ROE-41.71
ROIC-356
ROA-37.47
EBITDA, mln-185
EV / EBITDA-4.34
EV / EBIT-4.34

Quote Details

Last 17.07
Change -0.54 (-3.07%)
Open 17.53
Volume 712,297
Turnover 12,158,910
Average Volume 819,038

Financial Ratios

Leverage Ratio1.09
Current Ratio11.59
Price / Book2.64
Price / Tangible Book2.64
Debt / Equity0.00

Financial Strength

Piotroski F-Score 3 / 9
1-Year Target Price35.67
Short Ratio16.85
Short % of Float22.51

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 1.73% 77 / 100   
1 Month -13.7% 25 / 100   
2 Months -37.13% 13 / 100   
6 Months -24.64% 24 / 100   
1 Year 3.77% 55 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Blog